Kornimate/medical-research-clean huggingface dataset:
effectiveness of oral management strategies on improving oral frailty and oral bacteria

Conditions: Oral Hygiene; Pneumonia, Bacterial

Summary: the aim of this study is to examine the effectiveness of nurse-driven oral management for improvements of oral frailty, and oral bacteria pneumonia patients with oral frailty using a randomized controlled trial (rct) design. hospitalized pneumonia patients (n = 90) will be randomized into three groups (oral management, oral care, and standard of care). the primary outcomes include the oral frailty measures determined by seven-item included oral hygiene, oral dryness, occlusion force, tongue-lip motor function, tongue pressure, mastication function, and swallowing function. saliva samples were collected from the oral cavity before the bacterial culture was performed in the laboratory. oral frailty measures and the presence of bacterial exposure were evaluated at baseline (1st day), on days 5, and at the time of discharge. the investigators will perform statistical analyses according to the intention-to-treat principle. all missing values will be imputed using the last value carry-forward method. the between-group differences will be examined using a mixed model in which group and time interaction will be included. this study finding could provide oral management strategies that could improve oral frailty and decrease oral bacteria for preventing recurrent pneumonia infection among middle-aged and older adults with pneumonia.

the inclusion criteria will be as follows: (1) patients should be ≥ 50 years old; (2) patients' oral frailty should have been diagnosed with pneumonia, and (3) patients should have a glasgow coma index of 15 points and be able to cooperate. alternatively, the exclusion criteria will be as follows: (1) people with healthcare-related pneumonia; (2) those with head and neck cancer; or (3) those having an abnormal oral structure.

Eligibility criteria:
inclusion criteria: * older than 50 years of age and equal * having mental clarity (glasgow coma scale: 15) exclusion criteria: * a brief hospitalization (≤ 3 days) for non-acute care, such as uncomplicated elective percutaneous coronary intervention; * acute psychiatric syndromes; * received dental treatment in the last 6 months.

Keywords: pneumonia oral frailty oral bacteria oral management
using deep learning methods to analyze automated breast ultrasound and hand-held ultrasound images, to establish a diagnosis, therapy assessment and prognosis prediction model of breast cancer.

Conditions: Breast Cancer

Summary: the purpose of this study is using a deep learning method to analyze the automated breast ultrasound (abus) and hand-held ultrasound(hhus) images, establish and evaluate a diagnosis, therapy assessment and prognosis prediction model of breast cancer. the model would provide important references for further early prevention, early diagnosis and personalized treatment.

1. establishing a database by collecting abus, hhus and comprehensive breast images data, essential information, clinical treatment information, prognosis, and curative effect information, a complete breast image database is constructed. 2. marking abus images three doctors use a semi-automatic method to frame the lesions on the image. 3. building the model using the deep learning method to preprocess, analyze and train the marked images, and finally get a model diagnosis, efficacy evaluation and prognosis prediction model of breast cancer. 4. evaluating the model 1）self-validation： analyze the sensitivity, auc of the breast cancer diagnosis model and the false-positive number on each abus volume. 2) compared the sensitivity, auc and the false-positive number with a commercial diagnosis model. 3)to test the screening and diagnostic efficacy of computer-aided diagnosis systems through prospective or retrospective studies. 4)by analyzing the size and characteristics of the lesions after neoadjuvant chemotherapy, and predicting the os and dfs time, the therapy assessment and prognosis prediction model were evaluated.

Eligibility criteria:
inclusion criteria: 1. female patients over 18 years old who come to the two centers for physical examination or treatment; 2. complete basic information and image data exclusion criteria: 1. there is no complete abus and hhus images data; 2. the image quality is poor; 3. in multifocal breast cancer, the correlation between the tumor in the image and the postoperative pathological examination is uncertain.
the impact of a physical activity program on biomarkers of aging during chemotherapy for breast cancer

Conditions: Breast Cancer; Aging

Summary: this study will look at whether or not participating in a physical activity intervention during chemotherapy for breast cancer can prevent a marker of aging called p16 from having a large increase after chemotherapy.

our research team has determined that p16ink4a - a biomarker of aging -- increases dramatically during chemotherapy and that p16 levels among patients of similar age are lower among those who exercise. we hypothesize that engagement in physical activity during chemotherapy will have a moderating effect on increases in p16 levels during chemotherapy. to test this hypothesis, we propose to enroll 48 patients age 21-64 with a stage i-iii breast cancer diagnosis who are about to start adjuvant or neoadjuvant chemotherapy in a physical activity intervention program. our primary objective is to compare the change in p16 from baseline to end of chemotherapy for participants in this study (who are engaged in a physical activity intervention) to the mean change in p16 seen in a previous study of similar patients who did not participate in a physical activity intervention. as secondary objectives, we propose to evaluate (1) changes in treatment-related toxicity, physical function, fatigue, and quality of life between baseline, end of chemotherapy and 6 months post-chemotherapy, (2) the association of changes in p16 levels with changes in measures of treatment-related toxicity, physical function, fatigue, and quality of life, and (3) the association of changes in physical activity levels with changes in measures of treatment-related toxicity, physical function, fatigue, and quality of life.

Eligibility criteria:
inclusion criteria: * 21 to 59 years of age, female (a similar trial lccc 1226 explores physical activity in women 60 years and older and is now in progress. * histologically confirmed stage i, ii or iii breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis) * scheduled to begin an appropriate adjuvant or neo-adjuvant chemotherapy regimen as defined by nccn guidelines (www.nccn.org). patients receiving anti-her-2 therapy are eligible but the intervention will only be tested during the chemotherapy portion of the regimen. * english speaking * irb approved, signed written informed consent * approval from their treating physician to engage in moderate-intensity physical activity * patient-assessed ability to walk and engage in moderate physical activity * willing and able to meet all study requirements. exclusion criteria: * one or more significant medical conditions that in the physician's judgment preclude participation in the walking or strength training intervention. * unable to walk or engage in moderate-intensity physical activity.

Keywords: breast cancer walk with ease physical activity walking younger women cancer p16 aging biomarkers biomarkers of aging chemotherapy chemotherapy treatment adjuvant chemotherapy neoadjuvant chemotherapy
fatty acid regulation of platelet function in diabetes

Conditions: Thrombosis; Type 2 Diabetes Mellitus

Summary: this study investigates the potential protective effects of altering fatty acid in the platelet as a method for prevention of platelet activation and thrombosis in type 2 diabetes mellitus. fatty acids (omega-3 and omega-6) and their oxidized lipids will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls.

12-lipoxygenase and essential fatty acids such as omega-3 and omega-6 have been shown to play important roles in regulating platelet activation, but the underlying mechanisms have not been fully elucidated as well as their true protection from thrombosis. 12-lipoxygenase inhibition prevents platelet activation in part by inhibiting 12-lipoxygenase oxidation of free fatty acids in the platelet. these oxidized fatty acids are known to play both a pro- and anti-thrombotic effect on platelets depending on the fatty acid. oxidation of arachidonic acid by 12-lipoxygenase results in a pro-thrombotic bioactive lipid whereas oxidation of the omega-6 fatty acid dgla found in plant oil results in formation of a potent anti-thrombotic bioactive lipid. determining the extent of protection from this and other bioactive lipids produced through 12-lipoxygenase will allow for a better understanding of which fatty acid supplementation may best protect from thrombosis. essential fatty acids such as omega-3 (dha/epa) and omega-6 (dgla) appear to be protective. however the underlying mechanism for this potential protection is not well understood. identifying the mechanism by which these supplements protect from platelet activation may identify new approaches to preventing thrombotic events in this high risk population.

Eligibility criteria:
inclusion criteria: * healthy subjects and t2dm patients * african american and caucasian * t2dm patients on controlled medication (taking metformin) exclusion criteria: * dietary supplement within 2 weeks of enrollment * fish and plant oil supplements 2 months prior to enrollment * nsaids and aspirin 1 week prior to enrollment * smoking * cardiovascular event within 6 months prior to enrollment * other anti-platelet treatment including phosphodiesterase (pde) and p2y12r inhibitors * estimated glomerular filtration rate (egfr) below 30 (severe renal insufficiency) * egfr above 90

Keywords: platelets 12-lipoxygenase fatty acids dgla dha epa 12-lox
left atrial flutter: a comparison of ablation guided by high-density mapping and empirical linear ablation.

Conditions: Arrhythmias, Cardiac

Summary: unicenter, 1:1 randomized, open-labelled clinical trial comparing left atrial flutter ablation using high density mapping or strict lineal ablation. main outcome: arrhythmia recurrences over 1 year follow-up with daily 1-lead 30 seconds ecg samples.


Eligibility criteria:
inclusion criteria * left atrial flutter1 inducible during electrophysiological evaluation. * clinical indication for ablation: a) symptoms (palpitations, dizziness, syncope, breathlessness, derangement, heart failure), tachymiopathy, b) poor heart rate control, or c) recurrence after electrical cardioversion or failure of one antiarrhythmic drug. * informed consent. 1. patients will be enrolled if lafl is clinically suspected but finally randomized if this mechanism is established by electrophysiologic evaluation according to the criteria stated above. exclusion criteria * previous ablation of lafl. * previous linear ablation in the la except for pulmonary vein isolation. * absolute contraindication for oral anticoagulation. * stroke or acute coronary syndrome less than 3 months before ablation. * complex congenital heart disease.

Keywords: left atrial flutter linear ablation high-density mapping
aerobic training versus behavioral intervention to increase physical activity in patients with asthma

Conditions: Asthma

Summary: to compare the effects of aerobic training and behavioural intervention to increase physical activity in the clinical control of asthma and in the quality of life of patients with asthma.

adult participants of both genders with moderate to severe asthma, not physically active, will be evaluated after being informed about the study, agreeing and signing the informed consent form. participants will be randomized to aerobic training or behavioral intervention group. both interventions will consist of 8 weeks. aerobic training will be performed on a treadmill (2xweek; 45 min/session). the behavioral intervention will be a program to increase physical activity (1xweek; up to 90 min / session). the maximum hr will be estimated according to the tanaka's equation (208 - 0.7 x age).

Eligibility criteria:
inclusion criteria: 1. participants not physically active; 2. uncontrolled asthma (acq\>1,5); 3. diagnosis of asthma based on the recommendations of the global initiative for asthma (gina 2020); 4. be under outpatient follow-up at the pulmonology or immunology service of the university of sao paulo general hospital; 5. be under outpatient medical treatment for at least six months, with a stable clinical condition for at least 30 days; 6. being using optimized drug therapy for asthma. exclusion criteria: 1. participation in another research protocol; 2. difficulty in understanding any of the questionnaires used; 3. practitioners of regular physical activity; 4. pregnancy and psychiatric problems that make it difficult to understand the questionnaires and the study protocol; 5. presence of another chronic lung, neurological or musculoskeletal disease that hinders or prevents physical activity; 6. patients who are smokers or ex-smokers (who have quit smoking for less than 1 year or who have smoked more than 15 pack-years).

Keywords: asthma physical activity physical exercise quality of life
a study comparing the efficacy of two topical steroid application regimens in pediatric patients with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to investigate the efficacy of two different corticosteroid ointment application regimens for the treatment of eczema (atopic dermatitis).


Eligibility criteria:
inclusion criteria: * meet the clinical criteria for the diagnosis of atopic dermatitis * have disease over at least 5% of their total body surface area. * less than 18 years of age. * families able to comprehend written instructions in english and able to complete questionnaires with assistance if needed. * parents/guardians able to understand and willing to sign a parental permission form. * children between the ages of 7-17 years willing to sign an age-appropriate assent form. exclusion criteria: * patients who are allergic or intolerant of the topical medications employed in this study. * lack of follow-up after initial visit or regimen noncompliance. * patients who do not have access to a bathtub.

Keywords: atopic dermatitis topical corticosteroid pediatric eczema
association of cognition with functional mobility in people with alzheimer's disease

Conditions: Alzheimer Dementia; Alzheimer's Disease; Dementia, Alzheimer Type

Summary: this study aimed to investigate relationship between cognitive function and functional mobility in alzheimer's disease.

our hypothesis is that the decrease in cognitive function in individuals with alzheimer's disease is associated with the level of functional mobility. sociodemographic information of participants will be recorded. cognition will assessed with montreal cognitive assessment (moca), global score and moca's visuospatial executive functions, naming, attention, language, abstract thinking, delayed recall, orientation sub-scores will recorded. functional mobility will assessed timed up and go test and 5 times sit\&stand test.

Eligibility criteria:
inclusion criteria: * diagnosed with alzheimer's disease according to the national institute of --neurological and communicative disorders and stroke and the alzheimer's disease (nincds-adrda) criteria, * over 65 years old, * cases who could understand the instructions given in turkish were included in the study, * having ambulation skill independently or with walking aid. exclusion criteria: * dementia with lewy bodies, frontotemporal dementia and one of the other types of dementia, * having a pulmonary, neurological, musculoskeletal or rheumatological disease that may prevent exercise, * unstable medical condition (uncontrolled diabetes or hypertension, deep vein thrombosis, etc.), * subjects with visual or auditory deficits or behavioral problems that would make communication difficult were not included in the study.
mbcgt and psycho-physiological stress regulation group for depression and psycho-physiological stress patient

Conditions: Psychophysiologic Disorders; Stress, Psychological; Unipolar Depression

Summary: cases of physical and psychological stress problems is the need to prevent the risk of depression, primary care model will help to prevent depression. many scholars have advocated for depression treatment not only concern symptom control and relief, prevention of recurrence should also be aware. the literature found cases had depression, with cognitive strategy bias , may cause recurrence of depression, under the influence of stress. the study was to assist the physical and mental disorder patient caused by stress and depression patient having cognitive and emotional regulation, and increased adapting ability by ongoing two separate treatment groups ,mindfulness-based cognitive group therapy and psycho-physiological stress regulation group therapy. in addition, psychological groups can also help regulation daily trivia stress, study will try to know about how group therapy's effects on patient's immune system.research has three purposes,to validation 2 group model's results in assisting psycho-physiological stressed and depression patient, to establish group leader training center and prepare groups' standard procedure manuals,and to understand the patient's psycho-physical stress reaction on the immune system and fat cell hormone.

the study was to assist the physical and mental disorder patient caused by stress and depression patient having cognitive and emotional regulation, and increased adapting ability by ongoing two separate treatment groups ,mindfulness-based cognitive group therapy and psycho-physiological stress regulation group therapy. in addition, psychological groups can also help regulation daily trivia stress, study will try to know about how group therapy's effects on patient's immune system.research has three purposes,to validation 2 group model's results in assisting psycho-physiological stressed and depression patient, to establish group leader training center and prepare groups' standard procedure manuals,and to understand the patient's psycho-physical stress reaction on the immune system and fat cell hormone.

Eligibility criteria:
inclusion criteria: * physical and mental condition caused by stress, physician diagnosed * suffered from major depression, in remission more than three months , and had moderate or mild depressed mood exclusion criteria: * suffering from schizophrenia or anxiety disorder . * chronic diseases (such as diabetes, stroke, heart disease, cancer, etc.) or major injury (such as a car accident brain injury)

Keywords: psychotherapy, group
efficacy and safety of repeated intraarticular injections of hyaluronic acid in patients with oa of the knee

Conditions: Osteoarthritis of the Knee

Summary: the main objective is the long-term comparison (3 years and 4 months) of the efficacy and safety of repeated intra-articular administration of hyaluronic acid in the treatment of osteoarthritis of the knee.

to evaluate the efficacy and safety of repeated injections of hyaluronic acid compared with placebo over a period of 40 months.

Eligibility criteria:
inclusion criteria: * patient \> 45 years of age * out-patient diagnosed with primary osteoarthritis of the femorotibial medial joint of the knee with clinical and radiological (kellgren grade ii-iii) acr diagnosis * joint space width (jsw) \> 2mm * overall pain greater or equal to 55mm (vas - visual analogue scale 100mm) recorded in the knee,by the patient at any time during the week prior to the evaluation exclusion criteria: * overweight patients (body mass index \> 32). * pregnant and lactating women. women of child-bearinge age not using effective contraception * patients who have received intra-articular hyaluronic acid within the previous year and/or intra-articular steroids or articular lavage in the chosen knee,within the previous 3 months prior to their inclusion in the study. * aine administration within the 14 days prior to their inclusion in the study. * administration of glucosamine sulphate, chondroitin sulphate and diacerein within the 3 months prior to their inclusion in the study. * immunocompromised patients or patients receiving systemic immunosuppressive therapy. * patients with known sensitivity to ha, parcetamol or aines permitted as rescue medication. * patients who have received any investigational drug within 30 days prior to visit 1, or who are scheduled for the administration of an investigational drug other than the protocol product during this study. * patients with severely impaired central nervous system. * patients with coagulation alterations, despite receiving treatment. * patients with secondary osteoarthritis of the knee * patients having previously received surgery, including arthroscopy * patients with articular inflammatory disease
transversus thoracic muscle plane block for open heart surgery

Conditions: Pain, Acute; Pain, Chest

Summary: poststernotomy pain is a complication of cardiac surgery. poorly controlled pain is associated with myocardial ischemia, cardiac arrhythmias, hypercoagulability, pulmonary complications, and increased rates of delirium and wound infection. the transverse thoracic muscle plane (ttmp) block is a novel plane block that provide pain for sternotomy. the aim of this study was to evaluate the analgesic effect of ultrasound guided ttmp block in patients undergoing open heart surgery.


Eligibility criteria:
inclusion criteria: american society of anesthesiologist's physiologic state i-iii patients undergoing open heart surgery exclusion criteria: chronic pain bleeding disorders renal or hepatic insufficiency patients on chronic non-steroidal anti-inflammatory medications emergency cases
phase 1/2 dose finding and safety study of ibrutinib in pediatric subjects with chronic graft versus host disease (cgvhd)

Conditions: Chronic Graft Versus Host Disease

Summary: dose finding and safety study of ibrutinib in pediatric subjects with chronic graft versus host disease (cgvhd)


Eligibility criteria:
key eligibility: inclusion criteria: 1. part a: subjects with moderate or severe cgvhd after failure of 1 or more lines of systemic therapy 2. part b: subjects with moderate or severe cgvhd after failure of 1 or more lines of systemic therapy, or subjects with new onset moderate or severe cgvhd and in need of systemic immunosuppression 3. history of allogeneic stem cell transplantation 4. age * part a: ≥1 to \<12 years of age at the time of enrollment * part b: ≥1 to \<22 years of age at the time of enrollment 5. karnofsky or lansky (subjects \<16 years of age) performance status ≥60 key eligibility: exclusion criteria: 1. presence of single organ genito-urinary involvement as the only manifestation of cgvhd 2. received an investigational agent within 28 days before enrollment. 3. received donor lymphocyte infusion (dli) within 56 days before enrollment 4. progressive underlying malignant disease or active post-transplant lymphoproliferative disease 5. any uncontrolled infection or active infection requiring ongoing systemic treatment 6. known bleeding disorders 7. active hepatitis c virus (hcv) or hepatitis b virus (hbv)

Keywords: cgvhd chronic graft versus host disease pcyc1146im pediatric gvhd chronic 1146 pharmacyclics pcyc imbruvica ibrutinib immunology graft versus host disease corticosteroids prednisone pci32765 pcyc1146 refractory new onset graft versus host disease refractory graft versus host disease moderate cgvhd severe cgvhd moderate chronic graft versus host disease severe chronic graft versus host disease